ArticleRisk management and healthcare policy2025
Impact of Recurrence on Survival Prognosis and Key Risk Factors in Myxofibrosarcoma: A Single-Center Retrospective Study.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Myxofibrosarcoma (MFS) is a rare malignant fibrogenic soft tissue tumor with high propensity for recurrence. This study retrospectively analyzed the surgical treatment outcomes of patients with myxofibrosarcoma (MFS) at a single center to evaluate the impact of recurrence on survival prognosis. Methods: Clinical data from 80 patients who underwent surgical treatment for MFS between January 2015 and January 2023 were reviewed retrospectively. Postoperative follow-up was conducted to assess recurrence and overall survival. Kaplan-Meier survival analysis was used to estimate overall survival (OS) and compare survival curves. Patients were stratified into recurrence and recurrence-free groups based on recurrence status. Oncological prognosis, prognostic factors influencing survival and recurrence, and the association between recurrence and survival prognosis were examined. Results: Over a median follow-up period of 40.6 months, recurrence was observed in 38 patients (47.5%), including 16 patients with multiple recurrences. A total of 17 patients (21.3%) died, and the 5-year OS rate was 70.1%. Independent prognostic factors for OS included age, tumor size, and chemotherapy. The presence of a tumor adjacent to a major vessel or nerve, as well as involvement of the upper extremity, were identified as independent risk factors for recurrence. No statistically significant differences in survival prognosis were observed between patients with and without recurrence. Additionally, survival outcomes did not differ significantly between patients with a single recurrence and those with multiple recurrences. Conclusion: MFS exhibits a high recurrence rate, with multiple recurrences frequently occurring within three years postoperatively. However, both single and multiple recurrences, when managed with aggressive surgical intervention, may not had an adverse effect on overall survival. For tumors located near major vessels or nerves, achieving complete surgical resection and maintaining vigilant postoperative surveillance are essential to mitigate the risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.